In the second episode of the CAMEO podcast, principal investigator Jennifer Rymer and Dominick Angiolillo discuss their recent research examining cangrelor use in the setting of upstream P2Y12 inhibitor use. You can earn 0.25 CME credits for listening to this episode through the Duke One Link Continuing Education website. Visit ja.dh.duke.edu/ to create or login to your account and search for CAMEO in the “find a course” field. Follow the steps at duke.is/vy8w8 to register for a Duke OneLink account today. Jennifer Rymer, MD, MBA, is the John Bush Simpson Assistant Professor of Medicine at Duke University and Principal Investigator of the CAMEO registry. Dr. Rymer is an interventional cardiologist, and she is a faculty member at the Duke Clinical Research Institute. Dr. Rymer’s disclosures include advisory board and research funding from Chiesi, research funding from Idorsia, and research funding from Pfizer Pharmaceuticals. Dominick Angiolillo, MD, PhD, FACC, is Professor and Chief of the Division of Cardiology, Medical Director of the University of Florida Health Cardiovascular Center in Jacksonville, Medical Director of the Cardiovascular Research Program, and Program Director of the Interventional Cardiology Fellowship. Dr. Angiolillo’s disclosures include consulting fees or honoraria from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, Novartis, PhaseBio, PLx Pharma, Pfizer, Sanofi and Ventura, outside the present work; he has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, Renal Guard Solutions and Scott R. MacKenzie Foundation. Visit https://duke.is/6/rfys to view a transcript of this episode.
